ceftazidime Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 559 72558-82-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ceftazidime hydrate
  • ceftazidime
  • biotum
  • cefazid
  • ceftacidin
  • ceftazidine
  • tazicef
  • tazidime
  • ceftazidime sodium
  • ceftazidime pentahydrate
Semisynthetic, broad-spectrum antibacterial derived from CEPHALORIDINE and used especially for Pseudomonas and other gram-negative infections in debilitated patients.
  • Molecular weight: 547.58
  • Formula: C22H23N6O7S2
  • CLOGP: -3.75
  • LIPINSKI: 2
  • HAC: 13
  • HDO: 4
  • TPSA: 188.39
  • ALOGS: -5.11
  • ROTB: 9

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 g P
6 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 5 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 85 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 156.82 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.31 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.40 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.79 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.80 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 19, 1985 FDA COVIS INJECTABLES

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple organ dysfunction syndrome 116.36 20.19 86 8661 55591 53284728
Aplastic anaemia 106.84 20.19 43 8704 8278 53332041
Pathogen resistance 91.53 20.19 36 8711 6524 53333795
Toxic epidermal necrolysis 89.82 20.19 53 8694 23497 53316822
Acute kidney injury 80.74 20.19 147 8600 253721 53086598
Drug resistance 73.70 20.19 44 8703 19918 53320401
Septic shock 69.48 20.19 67 8680 62162 53278157
Pseudomonas infection 66.45 20.19 33 8714 10395 53329924
Hyperbilirubinaemia 58.84 20.19 31 8716 11038 53329281
Sepsis 57.22 20.19 93 8654 146336 53193983
Neutropenia 56.73 20.19 97 8650 159088 53181231
Infective pulmonary exacerbation of cystic fibrosis 55.80 20.19 30 8717 11126 53329193
Encephalopathy 53.56 20.19 46 8701 36762 53303557
Fatigue 53.05 20.19 27 8720 730479 52609840
Drug reaction with eosinophilia and systemic symptoms 49.78 20.19 42 8705 32758 53307561
Adenoviral hepatitis 49.60 20.19 11 8736 262 53340057
Mixed liver injury 49.36 20.19 20 8727 3913 53336406
Myoclonus 48.65 20.19 31 8716 15733 53324586
Patent ductus arteriosus 45.10 20.19 19 8728 4099 53336220
Vanishing bile duct syndrome 43.94 20.19 12 8735 687 53339632
Febrile neutropenia 42.81 20.19 68 8679 104868 53235451
Cytomegalovirus infection 42.61 20.19 31 8716 19508 53320811
Bronchopulmonary aspergillosis 42.49 20.19 23 8724 8642 53331677
Systemic inflammatory response syndrome 42.36 20.19 20 8727 5640 53334679
Cholestasis 42.02 20.19 36 8711 28659 53311660
Disseminated intravascular coagulation 40.11 20.19 30 8717 19689 53320630
Respiratory failure 39.44 20.19 64 8683 100448 53239871
Staphylococcal sepsis 38.97 20.19 21 8726 7819 53332500
Neurotoxicity 37.26 20.19 26 8721 15323 53324996
Pain 36.67 20.19 26 8721 588372 52751947
Venous haemorrhage 35.97 20.19 8 8739 193 53340126
Pancytopenia 35.81 20.19 58 8689 90870 53249449
Peritonitis 35.46 20.19 29 8718 21658 53318661
Hepatic failure 35.21 20.19 36 8711 35770 53304549
Status epilepticus 35.19 20.19 25 8722 15159 53325160
Endometrial disorder 34.88 20.19 10 8737 684 53339635
Suspected transmission of an infectious agent via product 34.69 20.19 8 8739 228 53340091
Pyrexia 34.57 20.19 144 8603 403049 52937270
Endophthalmitis 34.18 20.19 15 8732 3572 53336747
Myelosuppression 34.14 20.19 23 8724 12805 53327514
Intensive care unit acquired weakness 34.06 20.19 10 8737 744 53339575
Enterococcus test positive 33.88 20.19 11 8736 1144 53339175
Pseudomonal bacteraemia 31.69 20.19 11 8736 1404 53338915
Fall 31.20 20.19 10 8737 358430 52981889
Fungaemia 30.55 20.19 12 8735 2165 53338154
Graft versus host disease in gastrointestinal tract 30.18 20.19 13 8734 2961 53337358
Febrile bone marrow aplasia 29.56 20.19 17 8730 7172 53333147
Rash maculo-papular 29.41 20.19 30 8717 29719 53310600
Hepatocellular injury 29.21 20.19 30 8717 29956 53310363
Fungal sepsis 28.89 20.19 10 8737 1265 53339054
Micturition disorder 28.75 20.19 11 8736 1849 53338470
Graft versus host disease in liver 28.42 20.19 8 8739 512 53339807
Peripheral sensorimotor neuropathy 28.15 20.19 10 8737 1365 53338954
Graft versus host disease 27.06 20.19 16 8731 7106 53333213
Toxic encephalopathy 27.03 20.19 15 8732 5912 53334407
Tubulointerstitial nephritis 26.83 20.19 22 8725 16482 53323837
Arthralgia 26.61 20.19 20 8727 439763 52900556
Blood bilirubin increased 26.55 20.19 31 8716 35699 53304620
Acute generalised exanthematous pustulosis 26.33 20.19 18 8729 10263 53330056
Aspergillus infection 26.30 20.19 16 8731 7480 53332839
Stenotrophomonas infection 25.88 20.19 10 8737 1726 53338593
Bacteraemia 25.85 20.19 21 8726 15528 53324791
Abdominal discomfort 25.83 20.19 3 8744 221059 53119260
Eosinophilic pneumonia acute 25.26 20.19 7 8740 423 53339896
Pulmonary haemorrhage 24.85 20.19 15 8732 6918 53333401
Generalised oedema 24.28 20.19 20 8727 15079 53325240
Renal failure 23.87 20.19 57 8690 118395 53221924
Linear IgA disease 23.83 20.19 9 8738 1461 53338858
Hypopyon 23.66 20.19 8 8739 943 53339376
Hepatosplenic candidiasis 23.39 20.19 6 8741 269 53340050
Sweat test abnormal 23.38 20.19 4 8743 22 53340297
Aplasia 23.01 20.19 12 8735 4180 53336139
Product contamination 22.72 20.19 7 8740 614 53339705
Renal tubular necrosis 22.39 20.19 17 8730 11402 53328917
Ascites 22.36 20.19 30 8717 39705 53300614
Hepatic necrosis 22.06 20.19 13 8734 5737 53334582
Thrombocytopenia 22.01 20.19 61 8686 138666 53201653
Mucormycosis 21.98 20.19 10 8737 2590 53337729
Hepatomegaly 21.85 20.19 17 8730 11814 53328505
Headache 21.85 20.19 34 8713 536787 52803532
Graft versus host disease in skin 21.79 20.19 10 8737 2643 53337676
Congestive hepatopathy 21.78 20.19 10 8737 2646 53337673
Respirovirus test positive 21.56 20.19 4 8743 37 53340282
Myelopathy 21.51 20.19 10 8737 2721 53337598
Lower respiratory tract infection bacterial 21.45 20.19 6 8741 375 53339944
Alopecia 21.38 20.19 6 8741 234577 53105742
Peripheral swelling 21.31 20.19 4 8743 206104 53134215
Drug intolerance 21.22 20.19 4 8743 205489 53134830
Haemophagocytic lymphohistiocytosis 21.07 20.19 15 8732 9122 53331197
Hepatic function abnormal 20.98 20.19 28 8719 36871 53303448
Fibrosis 20.70 20.19 11 8736 3981 53336338
Klebsiella infection 20.59 20.19 14 8733 7912 53332407

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pathogen resistance 269.67 18.86 107 11105 9403 32492911
Endophthalmitis 239.36 18.86 78 11134 3871 32498443
Choroiditis 180.33 18.86 47 11165 1045 32501269
Septic shock 163.84 18.86 157 11055 68832 32433482
Multiple organ dysfunction syndrome 131.08 18.86 140 11072 69714 32432600
Drug resistance 122.55 18.86 84 11128 22881 32479433
Pseudomonas infection 112.56 18.86 63 11149 11993 32490321
Eye pain 103.10 18.86 61 11151 12887 32489427
Hyperbilirubinaemia 99.69 18.86 67 11145 17663 32484651
Intraocular pressure increased 98.26 18.86 45 11167 5613 32496701
Toxic epidermal necrolysis 90.64 18.86 67 11145 20526 32481788
Uveitis 87.29 18.86 43 11169 6307 32496007
Visual acuity reduced 66.78 18.86 51 11161 16394 32485920
Febrile neutropenia 63.20 18.86 132 11080 119434 32382880
Drug ineffective 60.25 18.86 276 10936 383201 32119113
Aplastic anaemia 59.37 18.86 35 11177 7338 32494976
Drug reaction with eosinophilia and systemic symptoms 58.86 18.86 64 11148 32421 32469893
Condition aggravated 57.21 18.86 149 11063 155512 32346802
Eosinophilia 53.87 18.86 54 11158 24904 32477410
Klebsiella infection 51.65 18.86 33 11179 7979 32494335
Fatigue 49.49 18.86 30 11182 350671 32151643
Fall 47.29 18.86 6 11206 196195 32306119
Pyrexia 44.11 18.86 222 10990 319746 32182568
Toxic skin eruption 42.77 18.86 34 11178 11580 32490734
Respiratory failure 39.72 18.86 103 11109 107079 32395235
Candida infection 39.31 18.86 38 11174 16765 32485549
Fungal sepsis 38.62 18.86 14 11198 956 32501358
Acute kidney injury 35.84 18.86 197 11015 293271 32209043
Cholestasis 35.22 18.86 45 11167 26988 32475326
Suspected transmission of an infectious agent via product 34.10 18.86 11 11201 527 32501787
Vascular pseudoaneurysm thrombosis 32.82 18.86 7 11205 62 32502252
Sepsis 32.31 18.86 124 11088 158710 32343604
Bronchopulmonary aspergillosis 32.10 18.86 31 11181 13656 32488658
Fungaemia 31.37 18.86 16 11196 2523 32499791
Clostridium difficile colitis 30.90 18.86 31 11181 14300 32488014
Acute respiratory distress syndrome 29.74 18.86 40 11172 25213 32477101
Acute generalised exanthematous pustulosis 27.92 18.86 21 11191 6592 32495722
Herpes zoster reactivation 27.61 18.86 8 11204 266 32502048
Febrile bone marrow aplasia 27.53 18.86 23 11189 8392 32493922
Product contamination 27.33 18.86 10 11202 701 32501613
Clostridium difficile infection 27.01 18.86 32 11180 17764 32484550
Cytokine release syndrome 26.86 18.86 28 11184 13507 32488807
Aspergillus infection 26.74 18.86 26 11186 11548 32490766
Cardiac valve vegetation 26.19 18.86 9 11203 525 32501789
Candida pneumonia 25.77 18.86 8 11204 338 32501976
Aplasia 25.46 18.86 17 11195 4425 32497889
Respiratory distress 24.81 18.86 44 11168 35202 32467112
Dizziness 24.23 18.86 22 11190 209596 32292718
Bone marrow failure 24.08 18.86 40 11172 30364 32471950
Thrombocytopenia 24.02 18.86 108 11104 148191 32354123
Neutropenia 23.37 18.86 104 11108 142071 32360243
Folliculitis 23.28 18.86 16 11196 4364 32497950
Pneumonia pseudomonal 23.22 18.86 15 11197 3694 32498620
Pseudomembranous colitis 23.21 18.86 14 11198 3058 32499256
Graft versus host disease 22.60 18.86 23 11189 10783 32491531
Death 22.57 18.86 63 11149 382454 32119860
Leukopenia 22.46 18.86 58 11154 60064 32442250
Chondritis 22.42 18.86 6 11206 148 32502166
Hepatocellular injury 22.36 18.86 35 11177 25283 32477031
Shock 22.23 18.86 34 11178 24080 32478234
Off label use 21.82 18.86 180 11032 306140 32196174
Pain 21.29 18.86 20 11192 187536 32314778
Listeriosis 21.12 18.86 9 11203 944 32501370
Stevens-Johnson syndrome 21.06 18.86 29 11183 18680 32483634
Liver abscess 20.99 18.86 14 11198 3637 32498677
Infective pulmonary exacerbation of cystic fibrosis 20.80 18.86 20 11192 8759 32493555
Encephalopathy 20.64 18.86 40 11172 34217 32468097
Status epilepticus 20.60 18.86 23 11189 11983 32490331
Device related sepsis 20.19 18.86 12 11200 2551 32499763
Flavobacterium infection 19.77 18.86 5 11207 98 32502216
Trichosporon infection 19.27 18.86 8 11204 787 32501527
Haemolytic anaemia 19.25 18.86 21 11191 10663 32491651
Fungal infection 19.24 18.86 25 11187 15230 32487084
Depression 19 18.86 5 11207 97055 32405259
Wound drainage 18.98 18.86 7 11205 502 32501812

Pharmacologic Action:

SourceCodeDescription
ATC J01DD02 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
ATC J01DD52 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Third-generation cephalosporins
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:50696 PBP3 inhibitor
CHEBI has role CHEBI:88188 allergenic drug
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Gonococcal meningitis indication 151004
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Ecthyma gangrenosum indication 17732003
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Streptococcal septicemia indication 29577008
Pneumonia due to Streptococcus indication 34020007
Pneumonia due to Pseudomonas indication 41381004
Peritonitis indication 48661000
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Rhinoscleroma indication 72409005 DOID:11336
Endometritis indication 78623009 DOID:1002
Septicemia due to Serratia indication 82091000
Bacterial meningitis indication 95883001 DOID:9470
Infection of bone indication 111253001
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Meningococcal meningitis indication 192644005
Proteus pneumonia indication 195888009
Neonatal meningitis indication 276674008
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Osteomyelitis due to Staphylococcus aureus indication 428783003
Sepsis due to Staphylococcus aureus indication 448417001
Sepsis due to Pseudomonas indication 448813005
Urinary tract infection caused by Klebsiella indication 369001000119100
H. Influenzae Meningitis indication
Enterobacter Osteomyelitis indication
E. Coli Cervicitis indication
Pseudomonas Aeruginosa Joint Infection indication
Pseudomonas Aeruginosa Osteomyelitis indication
E. Coli Pelvic Inflammatory Disease indication
Pseudomonas Aeruginosa Urinary Tract Infection indication
Complicated Proteus UTI indication
E. Coli Gynecological Infections indication
Skin and Skin Structure Proteus Infection indication
E. Coli Endometritis indication
Haemophilus Septicemia indication
Klebsiella Pneumoniae Peritonitis indication
Inflammatory Disease of Female Pelvic Organs indication
Skin and Skin Structure Serratia Infection indication
Enterobacter Pneumonia indication
E. Coli Pelvic Cellulitis indication
EnterobacterJoint Infection indication
Staphylococcus Aureus Joint Infection indication
Staphylococcus Peritonitis indication
Klebsiella Pneumoniae Osteomyelitis indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection indication
Klebsiella Joint Infection indication
E. Coli Peritonitis indication
Complicated UTI with Pseudomonas Aeruginosa indication
Citrobacter Pneumonia indication
Pyrexia of unknown origin off-label use 7520000
Pseudotuberculosis off-label use 36753006
Infection by Yersinia enterocolitica off-label use 80960004
Melioidosis off-label use 428111003 DOID:5052
Ventilator-acquired pneumonia off-label use 429271009
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis off-label use
Diabetic Foot Infection off-label use
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.53 acidic
pKa2 3.47 acidic
pKa3 13.61 acidic
pKa4 3.1 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ALLERGAN N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS 7112592 Jan. 7, 2026 A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ALLERGAN N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS 7112592 Jan. 7, 2026 A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNENUMONIA (HABP/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ALLERGAN N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS 7112592 Jan. 7, 2026 METHOD OF TREATING BACTERIAL INFECTIONS

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ALLERGAN N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS Feb. 25, 2020 NEW CHEMICAL ENTITY
EQ 0.5GM BASE;2GM/VIAL AVYCAZ ALLERGAN N206494 Feb. 25, 2015 RX POWDER INTRAVENOUS Feb. 25, 2025 GENERATING ANTIBIOTIC INCENTIVES NOW

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Peptidoglycan synthase FtsI Enzyme INHIBITOR IC50 6.26 WOMBAT-PK CHEMBL
Penicillin-binding protein 1A Enzyme INHIBITOR IC50 6.53 WOMBAT-PK CHEMBL
Penicillin-binding protein 1B Enzyme INHIBITOR IC50 4.96 WOMBAT-PK CHEMBL

External reference:

IDSource
4017550 VUID
N0000145931 NUI
D00921 KEGG_DRUG
C0007559 UMLSCUI
CHEBI:3508 CHEBI
CHEMBL44354 ChEMBL_ID
CHEMBL1200768 ChEMBL_ID
D002442 MESH_DESCRIPTOR_UI
DB00438 DRUGBANK_ID
10762 IUPHAR_LIGAND_ID
78439-06-2 SECONDARY_CAS_RN
9M416Z9QNR UNII
5481173 PUBCHEM_CID
203418 RXNORM
1047 MMSL
173313 MMSL
2299 MMSL
2303 MMSL
30973 MMSL
4383 MMSL
4384 MMSL
d00009 MMSL
002735 NDDF
006723 NDDF
006724 NDDF
36893000 SNOMEDCT_US
387200005 SNOMEDCT_US
725671004 SNOMEDCT_US
4017550 VANDF

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ceftazidime and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0264-3143 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 29 sections
Ceftazidime and Dextrose HUMAN PRESCRIPTION DRUG LABEL 1 0264-3145 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 29 sections
TAZICEF HUMAN PRESCRIPTION DRUG LABEL 1 0409-5082 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 24 sections
TAZICEF HUMAN PRESCRIPTION DRUG LABEL 1 0409-5084 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 24 sections
TAZICEF HUMAN PRESCRIPTION DRUG LABEL 1 0409-5086 INJECTION, POWDER, FOR SOLUTION 6 g INTRAVENOUS ANDA 24 sections
TAZICEF HUMAN PRESCRIPTION DRUG LABEL 1 0409-5092 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 25 sections
TAZICEF HUMAN PRESCRIPTION DRUG LABEL 1 0409-5093 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 25 sections
AVYCAZ HUMAN PRESCRIPTION DRUG LABEL 2 0456-2700 POWDER, FOR SOLUTION 2 g INTRAVENOUS NDA 29 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 25021-127 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 25021-127 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 26 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 25021-128 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 25021-128 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 25021-129 INJECTION, POWDER, FOR SOLUTION 6 g INTRAVENOUS ANDA 26 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 25021-129 INJECTION, POWDER, FOR SOLUTION 6 g INTRAVENOUS ANDA 26 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 44567-235 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 24 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 44567-236 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 24 sections
Ceftazidime HUMAN PRESCRIPTION DRUG LABEL 1 44567-237 INJECTION, POWDER, FOR SOLUTION 6 g INTRAVENOUS ANDA 25 sections
FORTAZ HUMAN PRESCRIPTION DRUG LABEL 1 52565-105 INJECTION, POWDER, FOR SOLUTION 100 mg INTRAMUSCULAR NDA 24 sections
FORTAZ HUMAN PRESCRIPTION DRUG LABEL 1 52565-106 INJECTION, POWDER, FOR SOLUTION 100 mg INTRAMUSCULAR NDA 24 sections
FORTAZ HUMAN PRESCRIPTION DRUG LABEL 1 52565-107 INJECTION, POWDER, FOR SOLUTION 170 mg INTRAMUSCULAR NDA 24 sections
FORTAZ HUMAN PRESCRIPTION DRUG LABEL 1 52565-109 INJECTION, POWDER, FOR SOLUTION 200 mg INTRAMUSCULAR NDA 25 sections